Literature DB >> 19587235

Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase.

Xingfeng Bao1, Motohiro Kobayashi, Shingo Hatakeyama, Kiyohiko Angata, Donald Gullberg, Jun Nakayama, Michiko N Fukuda, Minoru Fukuda.   

Abstract

Alpha-dystroglycan (alpha-DG) represents a highly glycosylated cell surface molecule that is expressed in the epithelial cell-basement membrane (BM) interface and plays an essential role in epithelium development and tissue organization. The alpha-DG-mediated epithelial cell-BM interaction is often impaired in invasive carcinomas, yet roles and underlying mechanisms of such an impaired interaction in tumor progression remain unclear. We report here a suppressor function of laminin-binding glycans on alpha-DG in tumor progression. In aggressive prostate and breast carcinoma cell lines, laminin-binding glycans are dramatically decreased, although the amount of alpha-DG and beta-dystroglycan is maintained. The decrease of laminin-binding glycans and consequent increased cell migration were associated with the decreased expression of beta3-N-acetylglucosaminyltransferase-1 (beta3GnT1). Forced expression of beta3GnT1 in aggressive cancer cells restored the laminin-binding glycans and decreased tumor formation. beta3GnT1 was found to be required for laminin-binding glycan synthesis through formation of a complex with LARGE, thus regulating the function of LARGE. Interaction of the laminin-binding glycans with laminin and other adhesive molecules in BM attenuates tumor cell migratory potential by antagonizing ERK/AKT phosphorylation induced by the components in the ECM. These results identify a previously undescribed role of carbohydrate-dependent cell-BM interaction in tumor suppression and its control by beta3GnT1 and LARGE.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19587235      PMCID: PMC2707272          DOI: 10.1073/pnas.0904515106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

1.  A unique molecular chaperone Cosmc required for activity of the mammalian core 1 beta 3-galactosyltransferase.

Authors:  Tongzhong Ju; Richard D Cummings
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-03       Impact factor: 11.205

2.  Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis.

Authors:  G Bergers; R Brekken; G McMahon; T H Vu; T Itoh; K Tamaki; K Tanzawa; P Thorpe; S Itohara; Z Werb; D Hanahan
Journal:  Nat Cell Biol       Date:  2000-10       Impact factor: 28.824

3.  A role for dystroglycan in epithelial polarization: loss of function in breast tumor cells.

Authors:  John Muschler; Dinah Levy; Roseanne Boudreau; Michael Henry; Kevin Campbell; Mina J Bissell
Journal:  Cancer Res       Date:  2002-12-01       Impact factor: 12.701

4.  Novel sulfated lymphocyte homing receptors and their control by a Core1 extension beta 1,3-N-acetylglucosaminyltransferase.

Authors:  J C Yeh; N Hiraoka; B Petryniak; J Nakayama; L G Ellies; D Rabuka; O Hindsgaul; J D Marth; J B Lowe; M Fukuda
Journal:  Cell       Date:  2001-06-29       Impact factor: 41.582

5.  p63 is a prostate basal cell marker and is required for prostate development.

Authors:  S Signoretti; D Waltregny; J Dilks; B Isaac; D Lin; L Garraway; A Yang; R Montironi; F McKeon; M Loda
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

6.  Identification and characterization of three novel beta 1,3-N-acetylglucosaminyltransferases structurally related to the beta 1,3-galactosyltransferase family.

Authors:  N Shiraishi; A Natsume; A Togayachi; T Endo; T Akashima; Y Yamada; N Imai; S Nakagawa; S Koizumi; S Sekine; H Narimatsu; K Sasaki
Journal:  J Biol Chem       Date:  2000-10-19       Impact factor: 5.157

7.  Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies.

Authors:  R M Grady; R W Grange; K S Lau; M M Maimone; M C Nichol; J T Stull; J R Sanes
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

8.  Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse.

Authors:  P K Grewal; P J Holzfeind; R E Bittner; J E Hewitt
Journal:  Nat Genet       Date:  2001-06       Impact factor: 38.330

9.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Authors:  Cheryl Longman; Martin Brockington; Silvia Torelli; Cecilia Jimenez-Mallebrera; Colin Kennedy; Nofal Khalil; Lucy Feng; Ravindra K Saran; Thomas Voit; Luciano Merlini; Caroline A Sewry; Susan C Brown; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2003-09-09       Impact factor: 6.150

10.  Opposing roles of integrin alpha6Abeta1 and dystroglycan in laminin-mediated extracellular signal-regulated kinase activation.

Authors:  Maria Ferletta; Yamato Kikkawa; Hao Yu; Jan F Talts; Madeleine Durbeej; Arnoud Sonnenberg; Rupert Timpl; Kevin P Campbell; Peter Ekblom; Elke Genersch
Journal:  Mol Biol Cell       Date:  2003-02-06       Impact factor: 4.138

View more
  47 in total

1.  Differential glycosylation of α-dystroglycan and proteins other than α-dystroglycan by like-glycosyltransferase.

Authors:  Peng Zhang; Huaiyu Hu
Journal:  Glycobiology       Date:  2011-09-19       Impact factor: 4.313

2.  Absence of post-phosphoryl modification in dystroglycanopathy mouse models and wild-type tissues expressing non-laminin binding form of α-dystroglycan.

Authors:  Atsushi Kuga; Motoi Kanagawa; Atsushi Sudo; Yiumo Michael Chan; Michiko Tajiri; Hiroshi Manya; Yamato Kikkawa; Motoyoshi Nomizu; Kazuhiro Kobayashi; Tamao Endo; Qi L Lu; Yoshinao Wada; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

3.  Mislocalization of fukutin protein by disease-causing missense mutations can be rescued with treatments directed at folding amelioration.

Authors:  Masaji Tachikawa; Motoi Kanagawa; Chih-Chieh Yu; Kazuhiro Kobayashi; Tatsushi Toda
Journal:  J Biol Chem       Date:  2012-01-24       Impact factor: 5.157

4.  Synthetic, structural, and biosynthetic studies of an unusual phospho-glycopeptide derived from α-dystroglycan.

Authors:  Kai-For Mo; Tao Fang; Stephanie H Stalnaker; Pamela S Kirby; Mian Liu; Lance Wells; Michael Pierce; David H Live; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2011-08-22       Impact factor: 15.419

5.  CDP-glycerol inhibits the synthesis of the functional O-mannosyl glycan of α-dystroglycan.

Authors:  Rieko Imae; Hiroshi Manya; Hiroki Tsumoto; Kenji Osumi; Tomohiro Tanaka; Mamoru Mizuno; Motoi Kanagawa; Kazuhiro Kobayashi; Tatsushi Toda; Tamao Endo
Journal:  J Biol Chem       Date:  2018-06-08       Impact factor: 5.157

6.  Reduced glycosylation of α-dystroglycans on carcinoma cells contributes to formation of highly infiltrative histological patterns in prostate cancer.

Authors:  Hisashi Shimojo; Motohiro Kobayashi; Takayuki Kamigaito; Yasuyo Shimojo; Minoru Fukuda; Jun Nakayama
Journal:  Prostate       Date:  2011-01-12       Impact factor: 4.104

7.  Small molecule schweinfurthins selectively inhibit cancer cell proliferation and mTOR/AKT signaling by interfering with trans-Golgi-network trafficking.

Authors:  Xingfeng Bao; Wanjun Zheng; Naoko Hata Sugi; Kishan L Agarwala; Qunli Xu; Zichun Wang; Karen Tendyke; Winnie Lee; Lana Parent; Wei Li; Hongsheng Cheng; Yongchun Shen; Noel Taylor; Zoltan Dezso; Hong Du; Yoshihiko Kotake; Nanding Zhao; John Wang; Maarten Postema; Mary Woodall-Jappe; Yasutaka Takase; Toshimitsu Uenaka; David G I Kingston; Kenichi Nomoto
Journal:  Cancer Biol Ther       Date:  2015-03-02       Impact factor: 4.742

8.  Mice lacking dystrophin or alpha sarcoglycan spontaneously develop embryonal rhabdomyosarcoma with cancer-associated p53 mutations and alternatively spliced or mutant Mdm2 transcripts.

Authors:  Karen Fernandez; Yelda Serinagaoglu; Sue Hammond; Laura T Martin; Paul T Martin
Journal:  Am J Pathol       Date:  2009-12-17       Impact factor: 4.307

9.  Loss of LARGE2 disrupts functional glycosylation of α-dystroglycan in prostate cancer.

Authors:  Alison K Esser; Michael R Miller; Qin Huang; Melissa M Meier; Daniel Beltran-Valero de Bernabé; Christopher S Stipp; Kevin P Campbell; Charles F Lynch; Brian J Smith; Michael B Cohen; Michael D Henry
Journal:  J Biol Chem       Date:  2012-12-06       Impact factor: 5.157

Review 10.  Sweetening the pot: adding glycosylation to the biomarker discovery equation.

Authors:  Penelope M Drake; Wonryeon Cho; Bensheng Li; Akraporn Prakobphol; Eric Johansen; N Leigh Anderson; Fred E Regnier; Bradford W Gibson; Susan J Fisher
Journal:  Clin Chem       Date:  2009-12-03       Impact factor: 8.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.